Lupin's Ranluspec™ Injection Approved by U.S. FDA

Created at 4 Jun · 03:39 UTC3 sources↑ Market-relevant3 events

IN SHORT

Lupin Limited announced that the U.S. FDA has approved its ranibizumab injection, Ranluspec™, for medical use. This approval marks a significant milestone for the global pharmaceutical company in the U.S. market.

Key Numbers

June 04, 2026date of approval announcement

Who's Involved

Lupin Limited

Global pharmaceutical company that received FDA approval

U.S. Food and Drug Administration (FDA)

Regulatory body that approved the drug

Ranluspec™

Ranibizumab injection approved by the FDA

Key facts

Lupin Limited received U.S. FDA approval for Ranluspec™ injection.
Ranluspec™ is a ranibizumab injection.
The approval was announced on June 4, 2026.

Lupin Limited announced on June 4, 2026, that the United States Food and Drug Administration (U.S. FDA) has approved its ranibizumab injection, Ranluspec™. This approval signifies a key advancement for the global pharmaceutical company within the U.S. market.

↳ Why This Matters

The FDA approval of Ranluspec™ allows Lupin to market its ranibizumab injection in the United States, potentially impacting the market for treatments of conditions addressed by this drug.

FREQUENTLY ASKED

Ranluspec™ is a ranibizumab injection developed by Lupin Limited.

The United States Food and Drug Administration (U.S. FDA) approved Ranluspec™.

The approval was announced on June 4, 2026.

What Happens Next

01Lupin will market Ranluspec™ in the United States.

02Further clinical use and market performance of Ranluspec™ will be observed.

Lupin's Ranluspec™ Injection Approved by U.S. FDA

PiQ Daily

Key facts

Lupin's Ranluspec™ Injection Approved by U.S. FDA

PiQ Daily

Key facts

Get the newsletter.